CN102335362A - Traditional Chinese medicine for treating insulin resistance of type 2 diabetes - Google Patents
Traditional Chinese medicine for treating insulin resistance of type 2 diabetes Download PDFInfo
- Publication number
- CN102335362A CN102335362A CN201110346174XA CN201110346174A CN102335362A CN 102335362 A CN102335362 A CN 102335362A CN 201110346174X A CN201110346174X A CN 201110346174XA CN 201110346174 A CN201110346174 A CN 201110346174A CN 102335362 A CN102335362 A CN 102335362A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- group
- type
- parts
- diabetes mellitus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 124
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 78
- 206010022489 Insulin Resistance Diseases 0.000 title abstract description 37
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 154
- 102000004877 Insulin Human genes 0.000 claims description 77
- 108090001061 Insulin Proteins 0.000 claims description 77
- 229940125396 insulin Drugs 0.000 claims description 77
- 210000000582 semen Anatomy 0.000 claims description 26
- 229940079593 drug Drugs 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 5
- 230000007812 deficiency Effects 0.000 abstract description 3
- 210000000952 spleen Anatomy 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000748223 Alisma Species 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 240000005373 Panax quinquefolius Species 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 72
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical group C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 52
- 210000002966 serum Anatomy 0.000 description 49
- 229960004586 rosiglitazone Drugs 0.000 description 26
- 102000016267 Leptin Human genes 0.000 description 21
- 108010092277 Leptin Proteins 0.000 description 21
- 229940039781 leptin Drugs 0.000 description 21
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 21
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 20
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 230000002496 gastric effect Effects 0.000 description 18
- 239000008103 glucose Substances 0.000 description 18
- 238000001802 infusion Methods 0.000 description 18
- 102000011690 Adiponectin Human genes 0.000 description 17
- 108010076365 Adiponectin Proteins 0.000 description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 16
- 230000000630 rising effect Effects 0.000 description 16
- 150000003626 triacylglycerols Chemical class 0.000 description 15
- 102000007156 Resistin Human genes 0.000 description 12
- 108010047909 Resistin Proteins 0.000 description 12
- 241000282894 Sus scrofa domesticus Species 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 102000002322 Egg Proteins Human genes 0.000 description 6
- 108010000912 Egg Proteins Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000007979 citrate buffer Substances 0.000 description 6
- 235000013345 egg yolk Nutrition 0.000 description 6
- 210000002969 egg yolk Anatomy 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 235000021590 normal diet Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003390 Chinese drug Substances 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 206010006100 Bradykinesia Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CKUVNOCSBYYHIS-SUEBGMEDSA-N (2r,3r,4s,5s,6r)-2-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-17-[(2r)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical group O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-SUEBGMEDSA-N 0.000 description 1
- WXHUQVMHWUQNTG-UHFFFAOYSA-N Alisol E 24-acetate Natural products CC12CCC(=O)C(C)(C)C1CCC1(C)C2C(O)CC2=C(C(CC(O)C(OC(C)=O)C(C)(C)O)C)CCC21C WXHUQVMHWUQNTG-UHFFFAOYSA-N 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 102000058015 Suppressor of Cytokine Signaling 3 Human genes 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- WXHUQVMHWUQNTG-JSWHPQHOSA-N [(3r,4s,6r)-2,4-dihydroxy-6-[(5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-3-oxo-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] acetate Chemical group C([C@@]12C)CC(=O)C(C)(C)[C@@H]1CC[C@@]1(C)[C@H]2[C@@H](O)CC2=C([C@@H](C[C@H](O)[C@@H](OC(C)=O)C(C)(C)O)C)CC[C@@]21C WXHUQVMHWUQNTG-JSWHPQHOSA-N 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
Abstract
The invention relates to a traditional Chinese medicine for treating insulin resistance of type 2 diabetes, and is used for solving the problem that the safe and efficient drugs for treating insulin resistance of type 2 diabetes are not available at present. The traditional Chinese medicine for treating insulin resistance of type 2 diabetes is prepared from the following components in parts by weight: 10-20 parts of American ginseng, 20-40 parts of coix seed and 10-20 parts of alisma. The traditional Chinese medicine has mild drug property and low toxic and side effect, and is used for treating insulin resistance of type 2 diabetes with the main characteristics, such as deficiency of spleen qi and interior accumulation of dampness and turbid. Compared with the similar traditional Chinese medicines, the traditional Chinese medicine has clear main active ingredients and definite disease treatment effect, and can obviously improve insulin resistance of type 2 diabetes.
Description
Technical field
The present invention relates to a kind of Chinese medicine of treating the type 2 diabetes mellitus insulin resistant.
Background technology
Type 2 diabetes mellitus is main with insulin resistant, with hypoinsulinism.Insulin resistant (insulin resistance; IR) be meant that body target organ or tissue reduce or forfeiture the sensitivity of insulin biological effect; The ability that produces insulin in the type 2 diabetes mellitus patient body is not to completely lose; Interior insulin of the patient's body that has even generation are too much, but the action effect of insulin is had a greatly reduced quality.Therefore, the intravital insulin of patient possibly be in a kind of state of relative shortage.Up to the present, from the doctor trained in Western medicine angle, also do not treat the ideal medicament of insulin resistant.The euglycemic agent that use does not stimulate insulin secretion is advocated in the treatment of insulin resistant more; But this type of medicine can promote fat generation; And fat closely related with insulin resistant and diabetes, so doctor trained in Western medicine is inevitably treated contradiction to the treatment existence of type 2 diabetes mellitus insulin resistant.The Chinese medicine disease is paid attention to determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs; Through the integrally-regulated pathological state of improving human body; Because Chinese medicine contains the number of chemical composition; Can be to a plurality of target spots of disease, resist at the treatment diabetes insulin and have special advantages aspect the complexity disease of this multifactor, many pathology target spot.Therefore, seek and further investigate the new Chinese medicine of treating the type 2 diabetes mellitus insulin resistant and become the major issue that the Chinese medicine worker needs to be resolved hurrily.Yet still lacking safely and effectively at present, Chinese medicine can be used to intervene the diabetes insulin opposing.
Summary of the invention
The present invention is the problem that will solve the safe and effective medicine that still lacks treatment type 2 diabetes mellitus insulin resistant at present, and a kind of Chinese medicine of treating the type 2 diabetes mellitus insulin resistant is provided.
The Chinese medicine that the present invention treats the type 2 diabetes mellitus insulin resistant is by weight by 10～20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 20～40 parts Semen Coicis and 10～20 parts is processed.
Radix Panacis Quinquefolii---function cures mainly: boosting qi and nourishing yin, clearing away heat and promoting production of body fluid.It is thanks to cloudy to be used for the deficiency of vital energy, interior-heat, and cough with asthma expectorant blood, deficiency-heat is tired tired, quenches one's thirst dryness of the mouth and throat.
Semen Coicis---function cures mainly: the spleen invigorating eliminating dampness by diuresis, and eliminating impediment antidiarrheal, row is dense in heat clearing away.Be used for edema, beriberi, dysuria, arthralgia chiefly caused by damp pathogen contracture, diarrhea due to hypofunction of the spleen, lung abscess, acute appendicitis.
Rhizoma Alismatis---function cures mainly: diuresis, clearing away damp-heat.Be used for dysuria, edema distension, the oliguria of having loose bowels, dizziness due to fluid-retention, the puckery pain of pyretic stranguria.
Treatment by Chinese herbs of the present invention is the type 2 diabetes mellitus insulin resistant determined curative effect of principal character to accumulate in deficiency of spleen-QI, the turbid damp.Herbal nature of the present invention is gentle, and toxic and side effects is little, compares with similar Chinese medicine, and its main active is clear, and the treatment disease is clear and definite, can obviously improve the type 2 diabetes mellitus insulin resistant.The active component of treatment type 2 diabetes mellitus insulin resistant mainly is 20 (R) ginsenoside Rb1 in the Radix Panacis Quinquefolii according to the invention; The active component of treatment type 2 diabetes mellitus insulin resistant mainly is Semen Coicis polysaccharide A in the said Semen Coicis; The active component of treatment type 2 diabetes mellitus insulin resistant mainly is Alisol A-24-acetate in the said Rhizoma Alismatis.
Chinese medicine of the present invention can reduce the fasting glucose (FBG) and the FPI (FINS) of insulin resistance rat, rising insulin sensitivity index (ISI), the abnormal carbohydrate metabolism when improving insulin resistant.
The rising of serum triglycerides (TG) level and the generation of insulin resistant (IR) and type 2 diabetes mellitus are closely related, high TG long-term with glucose competition entering cell in, thereby hindered oxidation and the utilization of glucose and caused blood sugar increasing.Free fatty (FFA) can suppress picked-up and the utilization of peripheral tissues to glucose, is one of main non-hormone substance that causes IR.Clinical research shows that the rising of plasma F FA can reduce the clearance rate of whole machine body to sugar, weakens the inhibitory action that endogenous glucose is generated and the rising blood glucose of insulin-mediated simultaneously.Disorders of lipid metabolism is increasing of triglyceride (TG) and free fatty (FFA) particularly, is the initiating agent that causes insulin resistant (IR).Chinese medicine of the present invention can significantly reduce insulin resistance rat serum triglycerides and free fatty acid levels, can correct disorders of lipid metabolism, improves the type 2 diabetes mellitus insulin resistant.
Phylaxin (Resistin) be find recently a kind of it can influence glucose metabolism relevant with insulin action and lipid metabolism by the excretory peptide hormone of adipose cell, because of the function that has glucagon is named as phylaxin.Resistin can influence the formation of insulin resistant through acting on several ways such as Insulin receptor INSR and IRS, rise Suppressor of Cytokine Signaling-3.Tumor necrosis factor-alpha (TNF-α) plays crucial effect in mechanism of insulin resistance.TNF-α regulates insulin action through acting on insulin signaling pathway, suppresses the insulin signaling transduction.Leptin (Leptin) can promote steatolysis; Suppress lipogenesis; Leptin can cause the insulin resistant of fatty tissue to the decomposition of fat itself; Be that lipogenesis reduces, decomposes and increase, produce a large amount of FFA and cause the insulin resistant of liver and muscle, so Leptin plays an important role in insulin resistant.Adiponectin (APN) is the excretory a kind of adipose cell factor of fatty tissue, is the fatty factor that unique and body fat content are negative correlation in the body, is that the contact carbohydrate tolerance is impaired, the important step of insulin resistant and diabetic angiopathy.Chinese medicine of the present invention can significantly reduce serum phylaxin, leptin, tumor necrosis factor-alpha level, and the adiponectin level that raises simultaneously can be improved the type 2 diabetes mellitus insulin resistant through fatty factor level more than regulating.
The specific embodiment
Technical scheme of the present invention is not limited to the following cited specific embodiment, also comprises the combination in any between each specific embodiment.
The specific embodiment one: the Chinese medicine of this embodiment treatment type 2 diabetes mellitus insulin resistant is by weight by 10～20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 20～40 parts Semen Coicis and 10～20 parts is processed.
The Chinese medicine of this embodiment treatment type 2 diabetes mellitus insulin resistant can be processed oral formulations such as pill, tablet, powder, granule, drop pill, oral liquid according to existing conventional method.
The specific embodiment two: what this embodiment and the specific embodiment one were different is: the Chinese medicine of treatment type 2 diabetes mellitus insulin resistant is by weight by 10 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 20 parts Semen Coicis and 10 parts is processed.Other is identical with the specific embodiment one.
The specific embodiment three: what this embodiment and the specific embodiment one were different is: the Chinese medicine of treatment type 2 diabetes mellitus insulin resistant is by weight by 20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 40 parts Semen Coicis and 20 parts is processed.Other is identical with the specific embodiment one.
The specific embodiment four: what this embodiment and the specific embodiment one were different is: the Chinese medicine of treatment type 2 diabetes mellitus insulin resistant is by weight by 15 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 40 parts Semen Coicis and 20 parts is processed.Other is identical with the specific embodiment one.
The specific embodiment five: what this embodiment and the specific embodiment one were different is: the Chinese medicine of treatment type 2 diabetes mellitus insulin resistant is by weight by 20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 25 parts Semen Coicis and 15 parts is processed.Other is identical with the specific embodiment one.
The specific embodiment six: what this embodiment and the specific embodiment one were different is: the Chinese medicine of treatment type 2 diabetes mellitus insulin resistant is by weight by 10 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 30 parts Semen Coicis and 20 parts is processed.Other is identical with the specific embodiment one.
The specific embodiment seven: the Chinese medicine of this embodiment treatment type 2 diabetes mellitus insulin resistant is by weight by 15 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 30 parts Semen Coicis and 15 parts is processed.
The Chinese medicine of this embodiment treatment type 2 diabetes mellitus insulin resistant can prepare by following method: get the Radix Panacis Quinquefolii of 15g by weight, the Semen Coicis of 30g and the Rhizoma Alismatis of 15g, the 3h that is soaked in water, decocting 1h then; Taking liquid, decocting 1h again, taking liquid; Merge medicinal liquid, be concentrated into 50mL, promptly get.
Experiment one: the Chinese medicine of this embodiment treatment type 2 diabetes mellitus insulin resistant is to glycometabolic influence
(1) type 2 diabetes mellitus insulin resistance rat Preparation of model
After 70 SD male rat adaptabilities fed for 1 week; Be divided into modeling group (60) and blank control group (10) at random; Blank control group feed normal diet, modeling group feed high lipid food (processing by 12% Adeps Sus domestica, 48% normal feedstuff, 15% sugar, 10% Semen arachidis hypogaeae, 10% egg yolk, 5% salt and 0.03% Fel Sus domestica salt) by the quality percentage composition.Feed (the 8th week) therebetween, the modeling group is injected 0.25% STZ solution (being dissolved in citric acid solution) by 25mg/Kg BW disposable celiac; The isopyknic citrate buffer of blank control group lumbar injection.After 10 weeks, detect each Mus fasting glucose and FPI level, calculate insulin sensitivity index (ISI).
(2) grouping and administration
With the insulin sensitivity index is screening index; Screening modeling success rat is 54 in the modeling group, is divided into the Chinese medicine high dose group (13) of this embodiment, Chinese medicine low dose group (13), rosiglitazone group (14) and the model group (14) of this embodiment at random.The Chinese medicine high dose group of this embodiment is pressed crude drug amount 10.8g/kg dosage gastric infusion; The Chinese medicine low dose group of this embodiment is pressed crude drug amount 5.4g/kg dosage gastric infusion; The rosiglitazone group is by 0.4mg/kg dosage gastric infusion (the rosiglitazone batch number is 0409002); Blank control group and model group are irritated the normal saline 10mL/kg of clothes equal volume every day.
(3) observation index
The general situation observation of rat: the situation such as food ration, body weight, outward appearance and behavior variation of observing rat.Detect the serum insulin level.Use blood glucose meter and detect fasting glucose (FBG); Adopt radioactive immunoassay to measure serum insulin (FINS); Calculate insulin sensitivity sex index ISI=ln [1/ (FBG * FINS)] simultaneously.
Data are used the SPSS software processes; The data of normal distribution representes that with
data of nonnormal distribution is carried out statistical analysis after all taking from right lognormalization.
(4) experimental result
The observation of the general situation of rat: before the modeling, each is organized, and activities in rats agility, fur are bright and clean, food ration, amount of drinking water, urine amount are all normal.Except that blank control group, all the other rat aggregate performances are lethargy, bradykinesia, hair is withered and yellow unglazed after the modeling, and food ration, amount of drinking water and urine amount increase.
The Chinese medicine of this embodiment is seen table 1 to the influence of rat fasting blood-glucose (FBG), FPI (FINS), insulin sensitivity index (ISI).
The Chinese medicine of this embodiment of table 1 is to the influence
of rat FBG, FINS and ISI
Annotate: 1. compare with blank control group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 1 result shows, compares with blank control group, and model group rat FBG, FINS level raise, and ISI descends, and significant difference (P＜0.01) is arranged, and explains that insulin resistant model duplicates successfully.Compare with model group, each administration group rat FBG, FINS descend (P＜0.01), and ISI raises (P＜0.05) to some extent simultaneously, and difference has statistical significance.The result shows that the Chinese medicine of this embodiment can reduce the FBG and the FINS of insulin resistance rat, rising ISI, the abnormal carbohydrate metabolism when improving insulin resistant.
Experiment two: the Chinese medicine of this embodiment treatment type 2 diabetes mellitus insulin resistant is to lipometabolic influence
(1) type 2 diabetes mellitus insulin resistance rat Preparation of model
After 70 SD male rat adaptabilities fed for 1 week; Be divided into modeling group (60) and blank control group (10) at random; Blank control group feed normal diet, modeling group feed high lipid food (processing by 12% Adeps Sus domestica, 48% normal feedstuff, 15% sugar, 10% Semen arachidis hypogaeae, 10% egg yolk, 5% salt and 0.03% Fel Sus domestica salt) by the quality percentage composition.Feed (the 8th week) therebetween, the modeling group is injected 0.25% STZ solution (being dissolved in citric acid solution) by 25mg/Kg BW disposable celiac; The isopyknic citrate buffer of blank control group lumbar injection.After 10 weeks, detect each Mus fasting glucose and FPI level, calculate insulin sensitivity index (ISI).
(2) grouping and administration
With the insulin sensitivity index is screening index; Screening modeling success rat is 54 in the modeling group, is divided into the Chinese medicine high dose group (13) of this embodiment, Chinese medicine low dose group (13), rosiglitazone group (14) and the model group (14) of this embodiment at random.The Chinese medicine high dose group of this embodiment is pressed crude drug amount 10.8g/kg dosage gastric infusion; The Chinese medicine low dose group of this embodiment is pressed crude drug amount 5.4g/kg dosage gastric infusion; The rosiglitazone group is by 0.4mg/kg dosage gastric infusion (the rosiglitazone batch number is 0409002); Blank control group and model group are irritated the normal saline 10mL/kg of clothes equal volume every day.
(3) concentration of triglyceride (TG), T-CHOL (TC) and these three kinds of materials of free fatty (FFA) in the detection serum.
(4) experimental result
The Chinese medicine of this embodiment of table 2 is to the influence
of rat blood serum T-CHOL, triglyceride
| Divide into groups | n | TG(mmol/L) | TC(mmol/L) |
| Blank control group | 10 | 0.69±0.21 | 1.78±0.14 |
| The Chinese medicine high dose group of this embodiment | 13 | 1.04±0.41 ★ | 1.88±0.52 ★★ |
| The Chinese medicine low dose group of this embodiment | 13 | 1.34±0.22 ★★ | 2.04±0.28 ★ |
| The rosiglitazone group | 14 | 1.25±0.30 ★★ | 1.96±0.46 ★★ |
| Model group | 14 | 2.15±0.19 ▲▲ | 3.36±0.32 ▲▲ |
Annotate: 1. compare with blank control group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
The Chinese medicine of this embodiment of table 3 is to the influence
of rat blood serum free fatty
| Divide into groups | n | FFA(μmol/L) |
| Blank control group | 10 | 656.2±89.7 |
| Model group | 14 | 1309.8±93.7 ▲▲ |
| The rosiglitazone group | 14 | 839.9±78.1 ★★ |
| The Chinese medicine high dose group of this embodiment | 13 | 861.6±75.8 ★★ |
| The Chinese medicine low dose group of this embodiment | 13 | 906.7±64.2 ★★ |
Annotate: 1. compare with blank control group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 2 and table 3 result show, compare model group rat blood serum T-CHOL (TC), triglyceride (TG) level rising (P＜0.01) with blank control group; Compare each administration group Serum TC, TG level decline (P＜0.01) with model group.Table 3 result shows, compares model group rat blood serum free fatty (FFA) level rising (P＜0.01) with blank control group; Compare each administration group rat blood serum FFA level decline (P＜0.01) with model group.Above experimental result shows that the Chinese medicine of this embodiment can obviously reduce serum TC, TG and the FFA level of insulin resistance rat, the hyperlipidemia state when improving insulin resistant.
Experiment three: to the influence of the fatty factor
(1) type 2 diabetes mellitus insulin resistance rat Preparation of model
After 70 SD male rat adaptabilities fed for 1 week; Be divided into modeling group (60) and blank control group (10) at random; Blank control group feed normal diet, modeling group feed high lipid food (processing by 12% Adeps Sus domestica, 48% normal feedstuff, 15% sugar, 10% Semen arachidis hypogaeae, 10% egg yolk, 5% salt and 0.03% Fel Sus domestica salt) by the quality percentage composition.Feed (the 8th week) therebetween, the modeling group is injected 0.25% STZ solution (being dissolved in citric acid solution) by 25mg/Kg BW disposable celiac; The isopyknic citrate buffer of blank control group lumbar injection.After 10 weeks, detect each Mus fasting glucose and FPI level, calculate insulin sensitivity index (ISI).
(2) grouping and administration
With the insulin sensitivity index is screening index; Screening modeling success rat is 54 in the modeling group, is divided into the Chinese medicine high dose group (13) of this embodiment, Chinese medicine low dose group (13), rosiglitazone group (14) and the model group (14) of this embodiment at random.The Chinese medicine high dose group of this embodiment is pressed crude drug amount 10.8g/kg dosage gastric infusion; The Chinese medicine low dose group of this embodiment is pressed crude drug amount 5.4g/kg dosage gastric infusion; The rosiglitazone group is by 0.4mg/kg dosage gastric infusion (the rosiglitazone batch number is 0409002); Blank control group and model group are irritated the normal saline 10mL/kg of clothes equal volume every day.
(3) concentration of detection serum phylaxin (Resistin), fat plain (APN), Serum Leptin Levels (Leptin) and tumor necrosis factor-alpha (TNF-α).
(4) experimental result
The Chinese medicine of this embodiment of table 4 is to the influence
of rat blood serum Resistin, APN
| Divide into groups | n | Resistin(ng/mL) | APN(ng/mL) |
| Blank control group | 10 | 13.74±3.05 | 4.31±0.68 |
| The Chinese medicine high dose group of this embodiment | 13 | 15.04±2.73 ★★ | 4.22±0.58 ★★ |
| The Chinese medicine low dose group of this embodiment | 13 | 15.86±2.19 ★ | 3.51±0.63 ★ |
| The rosiglitazone group | 14 | 19.47±3.24 | 3.98±0.51 ★★ |
| Model group | 14 | 19.65±3.11 ▲▲ | 2.53±0.62 ▲▲ |
Annotate: 1. compare with blank control group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 4 result shows, compares model group rat blood serum phylaxin (Resistin) level rising (P＜0.01) with blank control group; With model group relatively, star-spangled banner pool core group rat blood serum Resistin level descends, high dose group P＜0.01 wherein, low dose group P＜0.05.Compare model group rat blood serum adiponectin (APN) level decline (P＜0.01) with blank control group; With model group relatively, the Chinese drug-treated group rat blood serum APN level of this embodiment raises, high dose group P＜0.01 wherein, low dose group P＜0.05.
The Chinese medicine of this embodiment of table 5 is to the influence
of rat blood serum Leptin and TNF-α
| Divide into groups | n | Leptin(ng/mL) | TNF-a(ng/mL) |
| Blank control group | 10 | 2.548±0.523 | 1.873±0.194 |
| The Chinese medicine high dose group of this embodiment | 13 | 4.013±0.657 ★★ | 1.928±0.207 ★★ |
| The Chinese medicine low dose group of this embodiment | 13 | 4.563±0.692 ★★ | 2.197±0.223 ★ |
| The rosiglitazone group | 14 | 5.018±0.783 ★ | 2.054±0.215 ★★ |
| Model group | 14 | 5.906±0.628 ▲▲ | 2.549±0.201 ▲▲ |
Annotate: 1. compare with blank control group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 5 result shows, compares model group rat blood serum leptin (Leptin) level rising (P＜0.01) with blank control group; Compare the Chinese medicine high and low dose group rat blood serum Leptin level decline (P＜0.01) of this embodiment with model group.Compare model group rat blood serum tumor necrosis factor-alpha (TNF-α) level rising (P＜0.01) with blank control group; With model group relatively, the Chinese drug-treated group rat blood serum TNF-a level of this embodiment descends, high dose group P＜0.01 wherein, low dose group P＜0.05.
The Chinese medicine of this embodiment can significantly reduce serum phylaxin, leptin, tumor necrosis factor-alpha level, and the adiponectin level that raises simultaneously can be improved the type 2 diabetes mellitus insulin resistant through fatty factor level more than regulating.
The specific embodiment eight: the Chinese medicine of this embodiment treatment type 2 diabetes mellitus insulin resistant is by weight by 20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 30 parts Semen Coicis and 10 parts is processed.
The Chinese medicine of this embodiment treatment type 2 diabetes mellitus insulin resistant can prepare by following method: get the Radix Panacis Quinquefolii of 20g by weight, the Semen Coicis of 30g and the Rhizoma Alismatis of 10g, the 3h that is soaked in water, decocting 1h then; Taking liquid, decocting 1h again, taking liquid; Merge medicinal liquid, be concentrated into 50mL, promptly get.
Experiment one: the Chinese medicine of this embodiment treatment type 2 diabetes mellitus insulin resistant is to glycometabolic influence
(1) type 2 diabetes mellitus insulin resistance rat Preparation of model
After 70 SD male rat adaptabilities fed for 1 week; Be divided into modeling group (60) and blank control group (10) at random; Blank control group feed normal diet, modeling group feed high lipid food (processing by 12% Adeps Sus domestica, 48% normal feedstuff, 15% sugar, 10% Semen arachidis hypogaeae, 10% egg yolk, 5% salt and 0.03% Fel Sus domestica salt) by the quality percentage composition.Feed (the 8th week) therebetween, the modeling group is injected 0.25% STZ solution (being dissolved in citric acid solution) by 25mg/Kg BW disposable celiac; The isopyknic citrate buffer of blank control group lumbar injection.After 10 weeks, detect each Mus fasting glucose and FPI level, calculate insulin sensitivity index (ISI).
(2) grouping and administration
With the insulin sensitivity index is screening index; Screening modeling success rat is 54 in the modeling group, is divided into the Chinese medicine high dose group (13) of this embodiment, Chinese medicine low dose group (13), rosiglitazone group (14) and the model group (14) of this embodiment at random.The Chinese medicine high dose group of this embodiment is pressed crude drug amount 10.8g/kg dosage gastric infusion; The Chinese medicine low dose group of this embodiment is pressed crude drug amount 5.4g/kg dosage gastric infusion; The rosiglitazone group is by 0.4mg/kg dosage gastric infusion (the rosiglitazone batch number is 0409002); Blank control group and model group are irritated the normal saline 10mL/kg of clothes equal volume every day.
(3) observation index
The general situation observation of rat: the situation such as food ration, body weight, outward appearance and behavior variation of observing rat.Detect the serum insulin level.Use blood glucose meter and detect fasting glucose (FBG); Adopt radioactive immunoassay to measure serum insulin (FINS); Calculate insulin sensitivity sex index ISI=ln [1/ (FBG * FINS)] simultaneously.
Data are used the SPSS software processes; The data of normal distribution representes that with
data of nonnormal distribution is carried out statistical analysis after all taking from right lognormalization.
(4) experimental result
The observation of the general situation of rat: before the modeling, each is organized, and activities in rats agility, fur are bright and clean, food ration, amount of drinking water, urine amount are all normal.Except that blank control group, all the other rat aggregate performances are lethargy, bradykinesia, hair is withered and yellow unglazed after the modeling, and food ration, amount of drinking water and urine amount increase.
The Chinese medicine of this embodiment is seen table 1 to the influence of rat fasting blood-glucose (FBG), FPI (FINS), insulin sensitivity index (ISI).
The Chinese medicine of this embodiment of table 1 is to the influence
of rat FBG, FINS and ISI
Annotate: 1. compare with blank control group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 1 result shows, compares with blank control group, and model group rat FBG, FINS level raise, and ISI descends, and significant difference (P＜0.01) is arranged, and explains that insulin resistant model duplicates successfully.Compare with model group, each administration group rat FBG, FINS descend (P＜0.01), and ISI raises (P＜0.05) to some extent simultaneously, and difference has statistical significance.The result shows that the Chinese medicine of this embodiment can reduce the FBG and the FINS of insulin resistance rat, rising ISI, the abnormal carbohydrate metabolism when improving insulin resistant.
Experiment two: the Chinese medicine of this embodiment treatment type 2 diabetes mellitus insulin resistant is to lipometabolic influence
(1) type 2 diabetes mellitus insulin resistance rat Preparation of model
After 70 SD male rat adaptabilities fed for 1 week; Be divided into modeling group (60) and blank control group (10) at random; Blank control group feed normal diet, modeling group feed high lipid food (processing by 12% Adeps Sus domestica, 48% normal feedstuff, 15% sugar, 10% Semen arachidis hypogaeae, 10% egg yolk, 5% salt and 0.03% Fel Sus domestica salt) by the quality percentage composition.Feed (the 8th week) therebetween, the modeling group is injected 0.25% STZ solution (being dissolved in citric acid solution) by 25mg/Kg BW disposable celiac; The isopyknic citrate buffer of blank control group lumbar injection.After 10 weeks, detect each Mus fasting glucose and FPI level, calculate insulin sensitivity index (ISI).
(2) grouping and administration
With the insulin sensitivity index is screening index; Screening modeling success rat is 54 in the modeling group, is divided into the Chinese medicine high dose group (13) of this embodiment, Chinese medicine low dose group (13), rosiglitazone group (14) and the model group (14) of this embodiment at random.The Chinese medicine high dose group of this embodiment is pressed crude drug amount 10.8g/kg dosage gastric infusion; The Chinese medicine low dose group of this embodiment is pressed crude drug amount 5.4g/kg dosage gastric infusion; The rosiglitazone group is by 0.4mg/kg dosage gastric infusion (the rosiglitazone batch number is 0409002); Blank control group and model group are irritated the normal saline 10mL/kg of clothes equal volume every day.
(3) concentration of triglyceride (TG), T-CHOL (TC) and these three kinds of materials of free fatty (FFA) in the detection serum.
(4) experimental result
The Chinese medicine of this embodiment of table 2 is to the influence
of rat blood serum T-CHOL, triglyceride
| Divide into groups | n | TG(mmol/L) | TC(mmol/L) |
| Blank control group | 10 | 0.63±0.21 | 1.78±0.23 |
| The Chinese medicine high dose group of this embodiment | 13 | 1.01±0.51 ★ | 1.79±0.45 ★★ |
| The Chinese medicine low dose group of this embodiment | 13 | 1.33±0.18 ★★ | 2.04±0.25 ★ |
| The rosiglitazone group | 14 | 1.18±0.30 ★★ | 1.96±0.56 ★★ |
| Model group | 14 | 2.05±0.15 ▲▲ | 3.33±0.29 ▲▲ |
Annotate: 1. compare with blank control group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
The Chinese medicine of this embodiment of table 3 is to the influence
of rat blood serum free fatty
| Divide into groups | n | FFA(μmol/L) |
| Blank control group | 10 | 653.7±88.1 |
| Model group | 14 | 1279.9±95.4 ▲▲ |
| The rosiglitazone group | 14 | 834.9±79.4 ★★ |
| The Chinese medicine high dose group of this embodiment | 13 | 854.4±75.1 ★★ |
| The Chinese medicine low dose group of this embodiment | 13 | 900.2±65.2 ★★ |
Annotate: 1. compare with blank control group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 2 and table 3 result show, compare model group rat blood serum T-CHOL (TC), triglyceride (TG) level rising (P＜0.01) with blank control group; Compare each administration group Serum TC, TG level decline (P＜0.01) with model group.Table 3 result shows, compares model group rat blood serum free fatty (FFA) level rising (P＜0.01) with blank control group; Compare each administration group rat blood serum FFA level decline (P＜0.01) with model group.Above experimental result shows that the Chinese medicine of this embodiment can obviously reduce serum TC, TG and the FFA level of insulin resistance rat, the hyperlipidemia state when improving insulin resistant.
Experiment three: to the influence of the fatty factor
(1) type 2 diabetes mellitus insulin resistance rat Preparation of model
After 70 SD male rat adaptabilities fed for 1 week; Be divided into modeling group (60) and blank control group (10) at random; Blank control group feed normal diet, modeling group feed high lipid food (processing by 12% Adeps Sus domestica, 48% normal feedstuff, 15% sugar, 10% Semen arachidis hypogaeae, 10% egg yolk, 5% salt and 0.03% Fel Sus domestica salt) by the quality percentage composition.Feed (the 8th week) therebetween, the modeling group is injected 0.25% STZ solution (being dissolved in citric acid solution) by 25mg/Kg BW disposable celiac; The isopyknic citrate buffer of blank control group lumbar injection.After 10 weeks, detect each Mus fasting glucose and FPI level, calculate insulin sensitivity index (ISI).
(2) grouping and administration
With the insulin sensitivity index is screening index; Screening modeling success rat is 54 in the modeling group, is divided into the Chinese medicine high dose group (13) of this embodiment, Chinese medicine low dose group (13), rosiglitazone group (14) and the model group (14) of this embodiment at random.The Chinese medicine high dose group of this embodiment is pressed crude drug amount 10.8g/kg dosage gastric infusion; The Chinese medicine low dose group of this embodiment is pressed crude drug amount 5.4g/kg dosage gastric infusion; The rosiglitazone group is by 0.4mg/kg dosage gastric infusion (the rosiglitazone batch number is 0409002); Blank control group and model group are irritated the normal saline 10mL/kg of clothes equal volume every day.
(3) concentration of detection serum phylaxin (Resistin), fat plain (APN), Serum Leptin Levels (Leptin) and tumor necrosis factor-alpha (TNF-α).
(4) experimental result
The Chinese medicine of this embodiment of table 4 is to the influence
of rat blood serum Resistin, APN
| Divide into groups | n | Resistin(ng/mL) | APN(ng/mL) |
| Blank control group | 10 | 13.52±3.11 | 4.29±0.60 |
| The Chinese medicine high dose group of this embodiment | 13 | 15.75±2.52 ★★ | 4.22±0.54 ★★ |
| The Chinese medicine low dose group of this embodiment | 13 | 15.52±2.02 ★ | 3.51±0.73 ★ |
| The rosiglitazone group | 14 | 19.54±3.87 | 3.72±0.46 ★★ |
| Model group | 14 | 19.65±3.45 ▲▲ | 2.76±0.71 ▲▲ |
Annotate: 1. compare with blank control group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 4 result shows, compares model group rat blood serum phylaxin (Resistin) level rising (P＜0.01) with blank control group; With model group relatively, star-spangled banner pool core group rat blood serum Resistin level descends, high dose group P＜0.01 wherein, low dose group P＜0.05.Compare model group rat blood serum adiponectin (APN) level decline (P＜0.01) with blank control group; With model group relatively, the Chinese drug-treated group rat blood serum APN level of this embodiment raises, high dose group P＜0.01 wherein, low dose group P＜0.05.
The Chinese medicine of this embodiment of table 5 is to the influence
of rat blood serum Leptin and TNF-α
| Divide into groups | n | Leptin(ng/mL) | TNF-a(ng/mL) |
| Blank control group | 10 | 2.753±0.541 | 1.657±0.146 |
| The Chinese medicine high dose group of this embodiment | 13 | 3.956±0.543 ★★ | 1.975±0.251 ★★ |
| The Chinese medicine low dose group of this embodiment | 13 | 4.630±0.642 ★★ | 2.452±0.218 ★ |
| The rosiglitazone group | 14 | 5.247±0.764 ★ | 2.154±0.210 ★★ |
| Model group | 14 | 5.876±0.528 ▲▲ | 2.549±0.185 ▲▲ |
Annotate: 1. compare with blank control group:
▲P＜0.05,
▲ ▲2. compare with model group P＜0.01:
★P＜0.05,
★ ★P＜0.01
Table 5 result shows, compares model group rat blood serum leptin (Leptin) level rising (P＜0.01) with blank control group; Compare the Chinese medicine high and low dose group rat blood serum Leptin level decline (P＜0.01) of this embodiment with model group.Compare model group rat blood serum tumor necrosis factor-alpha (TNF-α) level rising (P＜0.01) with blank control group; With model group relatively, the Chinese drug-treated group rat blood serum TNF-a level of this embodiment descends, high dose group P＜0.01 wherein, low dose group P＜0.05.
The Chinese medicine of this embodiment can significantly reduce serum phylaxin, leptin, tumor necrosis factor-alpha level, and the adiponectin level that raises simultaneously can be improved the type 2 diabetes mellitus insulin resistant through fatty factor level more than regulating.
Claims (6)
1. Chinese medicine of treating the type 2 diabetes mellitus insulin resistant, the Chinese medicine that it is characterized in that treating the type 2 diabetes mellitus insulin resistant is by weight by 10～20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 20～40 parts Semen Coicis and 10～20 parts is processed.
2. a kind of Chinese medicine of treating the type 2 diabetes mellitus insulin resistant according to claim 1, the Chinese medicine that it is characterized in that treating the type 2 diabetes mellitus insulin resistant is by weight by 10 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 20 parts Semen Coicis and 10 parts is processed.
3. a kind of Chinese medicine of treating the type 2 diabetes mellitus insulin resistant according to claim 1, the Chinese medicine that it is characterized in that treating the type 2 diabetes mellitus insulin resistant is by weight by 20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 40 parts Semen Coicis and 20 parts is processed.
4. a kind of Chinese medicine of treating the type 2 diabetes mellitus insulin resistant according to claim 1, the Chinese medicine that it is characterized in that treating the type 2 diabetes mellitus insulin resistant is by weight by 15 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 40 parts Semen Coicis and 20 parts is processed.
5. a kind of Chinese medicine of treating the type 2 diabetes mellitus insulin resistant according to claim 1, the Chinese medicine that it is characterized in that treating the type 2 diabetes mellitus insulin resistant is by weight by 20 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 25 parts Semen Coicis and 15 parts is processed.
6. a kind of Chinese medicine of treating the type 2 diabetes mellitus insulin resistant according to claim 1, the Chinese medicine that it is characterized in that treating the type 2 diabetes mellitus insulin resistant is by weight by 10 parts Radix Panacis Quinquefolii, and the Rhizoma Alismatis of 30 parts Semen Coicis and 20 parts is processed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110346174 CN102335362B (en) | 2011-11-04 | 2011-11-04 | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110346174 CN102335362B (en) | 2011-11-04 | 2011-11-04 | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102335362A true CN102335362A (en) | 2012-02-01 |
| CN102335362B CN102335362B (en) | 2013-04-10 |
Family
ID=45511462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110346174 Expired - Fee Related CN102335362B (en) | 2011-11-04 | 2011-11-04 | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102335362B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138861A (en) * | 2015-04-05 | 2016-11-23 | 云南云百草实验室有限公司 | A kind of Chinese medicine treating type-II diabetes and preparation method thereof |
| CN112592396A (en) * | 2020-12-14 | 2021-04-02 | 上海交通大学 | Bioactive peptide VDPFSKKDW, and preparation method and application thereof |
-
2011
- 2011-11-04 CN CN 201110346174 patent/CN102335362B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 莫娜: "中医药治疗2 型糖尿病胰岛素抵抗用药分析", 《陕西中医》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138861A (en) * | 2015-04-05 | 2016-11-23 | 云南云百草实验室有限公司 | A kind of Chinese medicine treating type-II diabetes and preparation method thereof |
| CN112592396A (en) * | 2020-12-14 | 2021-04-02 | 上海交通大学 | Bioactive peptide VDPFSKKDW, and preparation method and application thereof |
| CN112592396B (en) * | 2020-12-14 | 2022-10-21 | 上海交通大学 | Bioactive peptide VDPFSKKDW as well as preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102335362B (en) | 2013-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1245187C (en) | Medicine for treating eye disease caused by visceral disease | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN115364170B (en) | Sugar metabolism regulator and preparation method and application thereof | |
| CN103948786A (en) | Traditional Chinese medicine for treating diabetes | |
| CN110075216B (en) | Food composition with auxiliary blood fat reducing, weight losing and liver protecting effects and preparation method, preparation and application thereof | |
| CN101856405A (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN101317959B (en) | Mastitis plaster for animals preparation and feeding method thereof | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN100427136C (en) | Medicinal composition for treating fatty liver, its preparation and use | |
| CN102335362B (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| CN102327340B (en) | Chinese medicine granular preparation for poultry and preparation method thereof | |
| CN101259191B (en) | Fat-reducing health products and producing method thereof | |
| CN102293928A (en) | Chinese medicinal composition for treating hyperuricemia and urarthritis, and preparation method and application thereof | |
| CN101491605A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN100467043C (en) | Chinese medicine for treating osteoporosis and its preparation | |
| CN103705578A (en) | Traditional Chinese medicine preparation with functions of reducing blood fat and inhibiting blood glucose increase and preparation method thereof | |
| CN100579564C (en) | Medicine for curing gout and its preparing method | |
| CN103417694A (en) | Traditional Chinese medicine used for treating diabetes | |
| CN106109951A (en) | Prevent and treat medicine of hyperglycemia, hyperlipidemia, hypertension and preparation method thereof | |
| CN103006891B (en) | Medicine composition for treating chronic renal failure | |
| CN100455317C (en) | Medicament for treating type 2 diabetes | |
| CN101468056B (en) | Chinese medicine preparation for treating enteritis, diarrhea, and red-white dysentery | |
| CN104740345B (en) | Treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN1186052C (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method | |
| CN108704036A (en) | A kind of Chinese traditional compound medicine and preparation method thereof for treating gout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ge Pengling Inventor after: Li Ji Inventor after: Sun Liying Inventor after: Wen Wei Inventor after: Sun Yang Inventor after: Yang Jing Inventor after: Yu Bocheng Inventor before: Ge Pengling Inventor before: Li Ji Inventor before: Sun Liying Inventor before: Wen Wei Inventor before: Sun Yang |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: GE PENGLING LI JI SUN LIYING WEN WEI SUN YANG TO: GE PENGLING LI JI SUN LIYING WEN WEI SUN YANG YANG JING YU BOCHENG |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ge Pengling Inventor after: Li Ji Inventor after: Sun Liying Inventor after: Wen Wei Inventor after: Sun Yang Inventor after: Yang Jing Inventor after: Yu Bocheng Inventor after: Ma Yuxuan Inventor before: Ge Pengling Inventor before: Li Ji Inventor before: Sun Liying Inventor before: Wen Wei Inventor before: Sun Yang Inventor before: Yang Jing Inventor before: Yu Bocheng |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: GE PENGLING LI JI SUN LIYING WEN WEI SUN YANG YANG JING YU BOCHENG TO: GE PENGLING LI JI SUN LIYING WEN WEI SUN YANG YANG JING YU BOCHENG MA YUXUAN |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130410 Termination date: 20181104 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |